European medical Journal. Urology最新文献

{"title":"The Unmet Need for Patients with Vitiligo is High","authors":"None AbbVie","doi":"10.33590/emjdermatol/10308718","DOIUrl":"https://doi.org/10.33590/emjdermatol/10308718","url":null,"abstract":"","PeriodicalId":90162,"journal":{"name":"European medical Journal. Urology","volume":"18 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135976177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Evaluation of Hair Loss: A Narrative Review","authors":"Abena Minta, Lucy Rose, Sonja Kobayashi, Brittany Dulmage","doi":"10.33590/emjdermatol/10302576","DOIUrl":"https://doi.org/10.33590/emjdermatol/10302576","url":null,"abstract":"The psychosocial impact of alopecia on the quality of life of patients underscores the importance of dermatologist readiness to evaluate this common chief complaint. When evaluating a patient presenting with new-onset hair loss, the differential diagnosis may be broad, encompassing many subtypes of hair loss. Each type of scarring or non-scarring alopecia presents with its own unique aetiology, epidemiology, clinical presentation, trichoscopic findings, and laboratory studies. Further, accurate diagnosis is needed to determine appropriate therapeutic management. This review provides a systematic approach for dermatologists to use in order to accurately diagnose hair loss disorders, including clinical examination, laboratory evaluation, and specialised tests.","PeriodicalId":90162,"journal":{"name":"European medical Journal. Urology","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134908484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Centricity in Skin Treatments: Global Meeting of Experts in Dermatology","authors":"Helen Boreham","doi":"10.33590/emjdermatol/10302314","DOIUrl":"https://doi.org/10.33590/emjdermatol/10302314","url":null,"abstract":"During this symposium, global experts in dermatology gave a series of lectures focused on skin treatments and their benefits for patients. Giuseppe Micali, University of Catania, Italy, provided a non-invasive skin imaging perspective on the skin journey over time, exploring the changes in the functional integrity of ageing skin, and associated dermatological needs. Positive findings from a clinical study evaluating U-Life™ 10 (Relife Menarini Group, Florence, Italy), a 10% urea cream, in the treatment of senile xerosis were also presented. The second lecture, presented by Giovanni Pellacani, Sapienza University, Rome, Italy, reviewed the pathogenesis of eczema, and the key role of oxidation in skin barrier impairment and inflammation. A recent study evaluating the clinical performance of Relizema™ cream (Menarini Group), a steroid-free medical device, for topical use demonstrated that it effectively reduced the severity of symptoms in adults with atopic and contact dermatitis, and was well-tolerated. The final presentation by Micali focused on salicylic acid-based products containing active ingredients that target multiple pathogenetic factors of acne. Findings from a multicentre, prospective, observational study of this new salicylic acid-based acne daily regimen showed promising improvements in patients with mild acne.","PeriodicalId":90162,"journal":{"name":"European medical Journal. Urology","volume":"44 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136058510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EADV 2023 Interview: Shyam Verma","authors":"Shyam Verma","doi":"10.33590/emjdermatol/10307834","DOIUrl":"https://doi.org/10.33590/emjdermatol/10307834","url":null,"abstract":"","PeriodicalId":90162,"journal":{"name":"European medical Journal. Urology","volume":"147 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136295125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shaping the Future of Coronary Interventions by Highlighting Coronary Anatomy and Reducing Contrast Volume","authors":"Ajay Kirtane, Javier Escaned, John Messenger, Haim Danenberg, Aaron Strobel","doi":"10.33590/emjintcardiol/10309765","DOIUrl":"https://doi.org/10.33590/emjintcardiol/10309765","url":null,"abstract":"Coronary interventions, and specifically the number of percutaneous coronary intervention (PCI) procedures, are increasing, together with their complexity. Contrast media administration during those procedures assists in visualising vessels anatomy, but also increases the risk of contrast-induced nephropathy (CIN), which remains one of the most common complications, and has been associated with poor clinical outcomes. Dynamic Coronary Roadmap (DCR) is a technology that creates a dynamic, motion-compensated, real-time view of the coronary anatomy overlaid on a 2D fluoroscopic image, creating a coloured map that adjusts automatically, and providing continuous visual feedback on the positioning of wires and catheters. The technology, which is already being used in clinical practice, has posed the promise of not only assisting in navigating wires and catheters, but also reducing the use of contrast during PCI. DCR4Contrast was a randomised clinical trial conducted in the USA, Europe, and Israel that enrolled more than 356 patients. The primary endpoint for the study was the reduction in contrast administered with the use of DCR, compared with the control group. The secondary endpoint was the potential reduction in the number of cineangiography runs. In the trial, DCR reduced the total contrast volume per PCI procedure by an average of 28.8%, and reduced the number of contrast-enhanced cineangiography runs per procedure by 26.3%. It was also demonstrated that the more complex the PCI procedure, the larger the reduction in contrast with DCR. Here, interventional cardiology experts discussed the need for contrast reduction, and the evidence for DCR.","PeriodicalId":90162,"journal":{"name":"European medical Journal. Urology","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134945590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2023 European Society of Cardiology (ESC) Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes","authors":"Robin Stannard","doi":"10.33590/emjcardiol/10301135","DOIUrl":"https://doi.org/10.33590/emjcardiol/10301135","url":null,"abstract":"The 2023 update of the European Society of Cardiology (ESC) guidelines for the management of cardiovascular disease (CVD) in patients with diabetes was presented in a symposium session at the ESC Congress 2023, held in Amsterdam, the Netherlands, from the 25th–28th of August. The updates redefined the 2019 guidelines, acknowledging recent findings from cardiovascular outcome trials (CVOT) on the safety and efficacy of glucose-lowering medications to provide practice-changing recommendations. The session also introduced a novel tool in predicting CVD risk, SCORE2-Diabetes, an innovative model that accounts for conventional and diabetes-related risk factors, stratified by geographical location.","PeriodicalId":90162,"journal":{"name":"European medical Journal. Urology","volume":"55 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135436211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PCSK9 Targeting in the Management of Hypercholesterolaemia","authors":"Constantine E. Kosmas, Evangelia J. Papakonstantinou, Jacqueline Carreño, Rogers Echavarria Uceta, Eliscer Guzman, Andreas Sourlas","doi":"10.33590/emjcardiol/10303462","DOIUrl":"https://doi.org/10.33590/emjcardiol/10303462","url":null,"abstract":"It has long been established that elevated plasma concentrations of low-density lipoprotein cholesterol (LDL-C) are among the prominent contributors leading to the development of atherosclerotic plaques and, ultimately, cardiovascular disease. In the current era of optimal risk factor modification, proprotein convertase subtilisin/kexin type 9 (PCSK9) targeting has emerged as a potent therapeutic approach in the management of hypercholesterolaemia, addressing several substantial, unmet clinical needs. PCSK9 monoclonal antibodies, evolocumab and alirocumab, as well as inclisiran, which is a small interfering RNA that halts the transcription of PCSK9 mRNA, are being increasingly used in current clinical practice, as they induce intensive LDL-C reductions without any significant safety and tolerability concerns. Based on the success of these agents, the concept of PCSK9 targeting with novel agents with enhanced biological properties, or via different administration routes, has received considerable attention. In this regard, numerous antisense oligonucleotides, peptides, and proteins are currently under evaluation in randomised controlled trials, yielding propitious results up to date; they may enter clinical use in the coming years. Meanwhile, a PCSK9 vaccine, as well as genome editing via clustered regularly interspaced palindromic repeats/Cas9, hold great promise to eradicate LDL-C altogether as a cardiovascular risk factor. This review aims to present and discuss the current clinical and scientific evidence pertaining to the field of medications that exert their biological effect by targeting PCSK9, which are either in use in clinical practice, or are currently being evaluated in pre-clinical or clinical studies, and may prove beneficial in the near future.","PeriodicalId":90162,"journal":{"name":"European medical Journal. Urology","volume":"72 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134975393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors and Patterns of Myocardial Injury in Patients with COVID-19: A Single-Centre Cohort Study","authors":"Muhammad Javed, Tehreem Zahid, Nasr-us-Salam Ghulam Akbar, Palwasha Alavi, Ammar Khalid Choudry, Maliha Aziz","doi":"10.33590/emjcardiol/10300480","DOIUrl":"https://doi.org/10.33590/emjcardiol/10300480","url":null,"abstract":"Objective: The primary objective was to compare the risk factors and trends of patients with COVID-19 with and without biochemical evidence of myocardial injury. Secondary objectives were the duration of hospitalisation, admission to an intensive care unit, mode of resuscitation, and use of supplemental O2. Design, and place and duration of study: This retrospective cohort study was conducted at Shifa International Hospitals, Islamabad, Pakistan. The study was conducted from May 2021–May 2022. Methodology: 113 patients admitted with a confirmed diagnosis of COVID-19 and troponin-I investigation were included in the study. Patients were divided into two groups: with and without myocardial injury on admission. Demographics, symptoms, diagnostics, vitals, comorbidities, and outcomes were noted. The χ2 exact test for categorical variables and independent t-test for continuous variables were used. All statistical analyses were performed with SPSS Statistics®, version 26.0 (IBM®, Armonk, New York, USA), with 0.05 as a level of significance. Results: Out of 113 patients, 47 patients (42%) had no myocardial injury on admission. The mean age of the patients was 63 years. Patients with myocardial injury were older, male, and unvaccinated against COVID-19 (p<0.01). No vital signs or presenting symptoms were statistically significant for myocardial injury. A comorbidity of hypertension on admission was suggestive of myocardial damage. Patients with myocardial injury had a higher risk of requiring resuscitation by cardiopulmonary resuscitation or pharmacologic means. Conclusion: Patients with myocardial injury did not have any impact on the composite of secondary outcomes, such as the duration of hospitalisation, admission to an intensive care unit, and use of supplemental O2.","PeriodicalId":90162,"journal":{"name":"European medical Journal. Urology","volume":"155 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135435847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-Based Differences in Short-Term Survival Following Out-of-Hospital Cardiac Arrest","authors":"Nertila Zylyftari, Filip Gnesin, Amalie Lykkemark Møller, Elisabeth Mills, Sidsel G. Møller, Britta Jensen, Kristian Bundgaard Ringgren, Frederik Folke, Gunnar Gislason, Christian Torp Pedersen, Christina Ji-Young Lee","doi":"10.33590/emjcardiol/10309244","DOIUrl":"https://doi.org/10.33590/emjcardiol/10309244","url":null,"abstract":"","PeriodicalId":90162,"journal":{"name":"European medical Journal. Urology","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134976044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adult Survivors of Childhood Cancer Have Significant Levels of Impaired Cardiorespiratory Fitness, Inflammatory Markers, and Poor Quality of Life Outcomes","authors":"C. McCune, C. Watson, M. Harbinson, A. McCarthy, R. Johnston, L. Dixon","doi":"10.33590/emjcardiol/10306774","DOIUrl":"https://doi.org/10.33590/emjcardiol/10306774","url":null,"abstract":"Anthracycline chemotherapy is used in approximately two thirds of the 35,000 European children diagnosed with cancer each year. Unfortunately 1 in 10 will develop symptomatic heart failure at 40 years after therapy. Emerging evidence suggests that anthracyclines exert a significant cardiovascular insult that expands beyond an impaired ejection fraction. Impaired cardiac reserve has been demonstrated in patients treated as adults however the impact of cancer treatment in childhood during cardiac development, is less widely described, particularly the long-term effects, several decades post treatment.\u0000 \u0000 \u0000 \u0000 This study explores quality of life (QOL), cardiorespiratory fitness and imaging outcomes in adult childhood cancer survivors (CCS) treated with >100mg/m2 of anthracycline.\u0000 \u0000 \u0000 \u0000 Adult CCS (>18 years) were recruited from our regional cardio-oncology surveillance programme. Anthracycline equivalence dose was calculated according to ESC 2022 guidance. Questionnaires were completed describing exercise habits and QOL (SF36). Outcomes in each domain were assessed against population age/gender matched normative values. A 6-minute walk test was performed and % predicted values adjusted for height/weight/age/gender (6MWT%). CCS with abnormal 6MWT% were referred for CPEX. Cardiac biomarker analysis (wrCRP, NTproBNP and TnT) and cardiac imaging were performed.\u0000 \u0000 \u0000 \u0000 Consent was gained from 86 CCS (55% male) mean age 28 (18-53 years). Mean dose was 270mg/m2 (108-705). 70% met NHS exercise targets. 49% were overweight or obese. 13% had an ejection fraction (EF) of <50% and 26% had an abnormal global longitudinal strain (GLS). 34 (40%) of patients had 6MWT% below the lower limit of normal (LLN). CCS scored below the LLN in every QOL domain, with marked abnormalities in general health (20% abnormal), mental health (16%) and physical functioning (13%).\u0000 Symptoms were similar in sedentary and non-sedentary patients. Sedentary CCS had abnormal wrCRP (p = 0.002), 6MWT% (p = 0.002) and lower indexed stroke volumes on MRI (p = 0.015). Exercise duration (mins/week) correlated with improved 6MWT%, fractional shortening, septal E/e’ (all P<0.05). Vigorous exercise compared to sedentary habits were associated with better 6MWT%, wrCRP, reduced frailty and improved QOL as well as NTproBNP, GLS and EF.\u0000 At 20 years post anthracycline, EF was impaired in 7/35 (20%), GLS impaired in 36% and 22% met criteria for frailty/prefrailty.\u0000 \u0000 \u0000 \u0000 Childhood cancer survivors display significant impairment in cardiorespiratory fitness and score lower in all quality of life domains. Sedentary behaviour is associated with worse QOL, impaired cardiorespiratory fitness, inflammation and abnormal imaging. Interestingly, reported symptoms did not differ regardless of activity level. Whether sedentary behaviour is secondary to cardiotoxicity or exercise mitigates the effect of cardiotoxicity is still unclear and further research is anticipated in this field.","PeriodicalId":90162,"journal":{"name":"European medical Journal. Urology","volume":"67 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134975115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}